Result for
Tag: immunity
November 24, 2020
Stable Neutralizing Antibody Levels Six Months after Mild and Severe COVID-19 Episode
Pre-print, not peer reviewed] Longitudinal analysis of 210 Spanish patients followed for up to 242 days showed that individuals with mild or asymptomatic SARS-CoV-2 infection experienced a negligible decay in neutralizing antibody activity that persisted for six months after symptom onset, while hospitalized individuals showed an initial rapid decline in neutralizing titers that significantly slowed…
November 23, 2020
Evidence of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection After Recovery from Mild Coronavirus Disease 2019
Genetic sequencing among 6 patients who retested positive for SARS-CoV-2 via rRT-PCR after recovery from initial infection identified one reinfection with a subtype of SARS-CoV-2 strain in the spike protein D614G substitution, that was genetically distinct from the initial infection. The positive test with the new strain occurred 26 days after the initial positive test…
November 18, 2020
Association between Exposure to Influenza Vaccination and COVID-19 Diagnosis and Outcomes
Influenza vaccination was associated with lower risk of COVID-19 diagnosis and hospitalization. Among 17,608 residents in Italy who tested for SARS-CoV-2 (28% positive), influenza vaccination (IV) was associated with lower risk of COVID-19 diagnosis (OR=0.9) in the overall cohort, and was associated with lower risk of COVID-19-related hospitalization (HR=0.7) and death (HR=0.7) in patients age…
November 17, 2020
Prevalence of IgG Antibodies against the Severe Acute Respiratory Syndrome Coronavirus-2 among Healthcare Workers in Tennessee during May and June 2020
[Pre-print, not peer reviewed] SARS-CoV-2 seroprevalence was low (<1%) among a large cohort of healthcare workers (HCWs) in Tennessee (n=11,787) from May to June 2020, despite sustained community-wide transmission during the same time period. Differences in seroprevalence across facilities reflected the differences in levels of community transmissions, with higher prevalence among HCWs located in urban…
November 16, 2020
Sex Differences in the Decline of Neutralizing Antibodies to SARS-CoV-2
[Pre-print, not peer-reviewed] A longitudinal study of sera from 308 SARS-CoV-2 RT-PCR positive individuals found that males exhibited a faster decline in anti-S and neutralizing antibodies than females, suggesting that the duration of protection may differ by sex. Higher levels of antibodies were observed one month after symptom onset among males, people over age 50,…
November 12, 2020
Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production
Analysis of longitudinal antibody responses of 76 COVID-19 patients followed for approximately 100 days showed that while anti-spike protein IgG levels declined rapidly for most individuals, those with sustained (and in some instances increased) anti-spike protein IgG levels experienced shorter disease course (median 10 vs. 16 days). Being an antibody “sustainer” also predicted persistent neutralizing…
Seasonal Human Coronavirus Antibodies Are Boosted upon SARS-CoV-2 Infection but Not Associated with Protection
[Pre-print, not peer reviewed] An analysis suggests that prior infection with human coronaviruses other than SARS-CoV-2 is not associated with protection from SARS-CoV-2 infection. The authors found no significant differences in the levels of pre-pandemic human coronavirus antibodies cross-reactive to SARS-CoV-2 proteins between a cohort of people eventually infected with SARS-CoV-2 (n=251) and a matched…
November 10, 2020
Longitudinal Characterization of the IgM and IgG Humoral Response in Symptomatic COVID-19 Patients Using the Abbott Architect
A longitudinal analysis of 1,349 serum samples collected up to 168 days post symptom onset from 427 individuals with PCR-confirmed COVID-19 found that IgM seroconversion occurs earlier than IgG, but that IgM levels decline to a greater extent over time. The median duration of time for IgM seroconversion was 10 days, but seroprevalence declined steadily…
November 9, 2020
Preexisting and de Novo Humoral Immunity to SARS-CoV-2 in Humans
Using flow cytometry, SARS-CoV-2 spike glycoprotein (S)-reactive IgG antibodies were detected in 6 of 65 SARS-CoV-2-uninfected individuals (5 with RT-qPCR-confirmed seasonal human coronaviruses [HCoVs] infection and 1 without recent HCoV infection). The authors conclude that this may suggest the presence of cross-reactive immunological memory from preexisting infection rather than de novo immunity. Ng et al. (Nov…
November 5, 2020
Lack of Antibodies to SARS-CoV-2 in a Large Cohort of Previously Infected Persons
A total of 6.3% of 2,547 healthcare workers and first responders in the New York City and Detroit metropolitan areas with previous confirmed SARS-CoV-2 infection were seronegative. Among symptomatic persons, the proportion seronegative was largely stable between 2 weeks and 90 days following symptom onset. The proportion seronegative ranged from 0% among 79 persons previously…
Previous page Next page